Adjuvant AI therapy for breast cancer: 10 years is superior to 5 years

CHICAGO – Extending adjuvant aromatase inhibitor (AI) therapy from 5 years to 10 years further reduces the risk of recurrence and new breast cancer in postmenopausal women treated for early disease,...
Source: Ob.Gyn. News - Category: OBGYN Source Type: research